These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 18508573)

  • 1. New insights in drug development for the non-small cell lung cancer therapy.
    Gridelli C; Rossi A; Maione P; Ferrara C; Del Gaizo F; Guerriero C; Nicolella D; Palazzolo G; Falanga M; Colantuoni G
    Front Biosci; 2008 May; 13():5108-19. PubMed ID: 18508573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
    Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational agents in the management of non-small cell lung cancer.
    Pennell NA; Mekhail T
    Curr Oncol Rep; 2009 Jul; 11(4):275-84. PubMed ID: 19508832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
    Blackledge G; Averbuch S
    Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR pathway in advanced non-small cell lung cancer.
    Merlo V; Longo M; Novello S; Scagliotti GV
    Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted therapies in the treatment of advanced/metastatic NSCLC.
    Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
    Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Targeted therapies in the treatment of non-small cell lung cancer].
    De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
    Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
    Wheler J; Falchook G; Tsimberidou AM; Hong D; Naing A; Piha-Paul S; Chen SS; Heymach J; Fu S; Stephen B; Fok JY; Janku F; Kurzrock R
    Oncotarget; 2013 May; 4(5):772-84. PubMed ID: 23800712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting epidermal growth factor receptor in lung cancer.
    Baselga J; Albanell J
    Curr Oncol Rep; 2002 Jul; 4(4):317-24. PubMed ID: 12044241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
    Thomas M
    Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histology matters: individualizing treatment in non-small cell lung cancer.
    Neal JW
    Oncologist; 2010; 15(1):3-5. PubMed ID: 20086166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments of targeted therapies in the treatment of non-small cell lung cancer.
    Rossi A; Maione P; Colantuoni G; Ferrara C; Rossi E; Guerriero C; Nicolella D; Falanga M; Palazzolo G; Gridelli C
    Curr Drug Discov Technol; 2009 Jun; 6(2):91-102. PubMed ID: 19519336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
    Grenier J; Soria JC
    Bull Cancer; 2007 Jan; 94(1):53-61. PubMed ID: 17237005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.